Willgo CR Tablet

The controlled-release formulation of Willgo CR Tablet ensures a sustained plasma concentration of the active ingredient, providing prolonged analgesic and anti-inflammatory effects while minimizing dosing frequency and enhancing patient compliance. This medication is typically administered orally, with or after meals, to reduce gastrointestinal irritation. It is contraindicated in patients with known hypersensitivity to Aceclofenac or other NSAIDs, active peptic ulceration, severe hepatic or renal impairment, and during the third trimester of pregnancy.

Caution is advised in patients with cardiovascular disease, hypertension, or a history of gastrointestinal bleeding. Common adverse effects may include gastrointestinal discomfort, dyspepsia, nausea, and dizziness. Patients should be monitored for signs of adverse reactions, and therapy should be discontinued if serious side effects occur. Willgo CR Tablet should be used under medical supervision, adhering to prescribed dosages to optimize therapeutic outcomes and minimize risks.